Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at 177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 -- its Alzheimer's disease agitation drug. The news drew analyst praise, with Needham and TD Cowen reiterating "buy" ratings on the stock, and the former lifting its price target to 169 from $154. On track for its largest single-day percentage gain since February, AXSM hit a record peak of$178.99 today. Should t ...